Evidence map›Paper›PMID 9122229›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1997

Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis.

D C Hooper, O Bagasra, J C Marini, A Zborek, S T Ohnishi, R Kean, J M Champion, A B Sarker, L Bobroski, J L Farber and 3 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
47.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 333 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells.Experimental biology and medicine (Maywood, N.J.) · 2021
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017
    Article
  17. Article
  18. NO-tryptophan: a new small molecule located in the rat brain.European journal of histochemistry : EJH · 2016
    Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

D C HooperDepartment of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
O Bagasra
J C Marini
A Zborek
S T Ohnishi
R Kean
J M Champion
A B Sarker
L Bobroski
J L Farber
T Akaike
H Maeda
H Koprowski
Thomas Jefferson University · USKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study we provide further evidence associating activated cells of the monocyte lineage with the lesions of multiple sclerosis (MS). Using a combination of immunohistochemistry and reverse transcriptase-dependent in situ polymerase chain reaction analysis, we have identified monocytes expressing inducible nitric oxide synthase (iNOS) to be prevalent in the plaque areas of post mortem brain tissue from patients with MS. In addition, we have obtained evidence of the nitration of tyrosine residues in brain areas local to accumulations of iNOS-positive cells. In parallel studies we have assessed the effects of inhibitors of iNOS induction, as well as scavengers of nitric oxide and peroxynitrite in the experimental allergic encephalomyelitis model. Significant therapeutic effects were seen with the inhibitor of iNOS induction, tricyclodecan-9-xyl-xanthogenate, a nitric oxide scavenger, 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, and a peroxynitrite scavenger, uric acid. In particular, treatment with high doses of uric acid virtually prevented clinical symptoms of the disease. Together with our demonstration of the presence of activated macrophages expressing high levels of iNOS and evidence of peroxynitrite formation in brain tissue from patients with MS, these findings are of importance in the development of approaches to treat this disease.

Indexed as

AnimalsBrainBridged-Ring CompoundsCyclic N-OxidesEncephalomyelitis, Autoimmune, ExperimentalEnzyme InductionFemaleFree Radical ScavengersHumansImidazolesMiceMice, Inbred StrainsMonocytesMultiple SclerosisNitratesNitric Oxide2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxideBridged-Ring CompoundsCyclic N-OxidesFree Radical ScavengersImidazolesNitratesNitric OxideNitric Oxide SynthaseNorbornanesperoxynitric acidRNA, MessengerThiocarbamatesThionestricyclodecane-9-yl-xanthogenateUric Acid

Identifiers

PMID9122229
PMCPMC20122
OpenAlexW1989639366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.